Frenelle Pharma Announces Advancement Across Pipelines, Validating Hub-and-Spoke Model
PLYMOUTH, Minn. – May 11, 2026 – Frenelle Pharma, a pioneering biotech portfolio company leveraging its proprietary Faros™ long-acting injectable technology, today announced pipeline progress across its subsidiaries, further validating its hub-and-spoke development model.
Frenelle PBC, the public benefit corporation collaborating with Mayo Clinic on substance use disorder treatments, recently announced the successful completion of a pharmacokinetic (PK) and toxicology (tox) study for FRN01, its lead 30-day subcutaneous buprenorphine injection for the treatment of opioid use disorder (OUD). FRN01 utilizes Frenelle Pharma’s proprietary Faros™ long-acting injectable technology, designed to deliver consistent, sustained drug release while supporting improved patient experience and adherence.
Anumio, Frenelle Pharma’s animal health subsidiary focused on companion animal therapeutics, has announced the selection of its lead asset, ANM02, a 90-day injectable phenylpropanolamine (PPA) product for the treatment of canine urinary incontinence. ANM02 is designed to deliver sustained symptom control from a single injection, decreasing the need for frequent dosing while supporting better treatment adherence and enhancing quality of life for pets and their owners. This milestone positions Anumio to rapidly progress toward proof-of-concept studies while capitalizing on the growing $29B companion animal drug market.
“These parallel advancements across human health and animal health subsidiaries demonstrate the power of our hub-and-spoke model,” said Jeff Missling, CEO of Frenelle Pharma. “By systematically de-risking multiple programs through our shared Faros™ platform, we create diversified value inflection points while maintaining capital efficiency across our portfolio.”
Frenelle Pharma welcomes inquiries from strategic partners and investors interested in its therapeutic area-focused subsidiaries and co-development opportunities for Faros™ technology.
About Frenelle Pharma
Frenelle Pharma systematically advances Faros™-enabled therapeutics from discovery through commercialization via its hub-and-spoke model. With micro-sized, spherical, non-porous particles that deliver consistent drug release, Faros™ particles enable injections through very small-gauge needles, minimizing injection-site pain and enhancing the safety of soft-tissue injections. Its aerodynamic properties make it compatible with inhalation as well. Frenelle Pharma has three subsidiaries at this time: SpineThera (sciatica), Frenelle PBC (addiction medicine), and Anumio (animal health). Headquartered in Minnesota's Medical Alley, the company is committed to continually improving patient and pet experiences through superior drug delivery. Learn more at frenellepharma.com.
Media Contact:
Jeff Missling, CEO
Frenelle Pharma